Upstate NY Cancer Symposium: June 21st (Buffalo, NY). Register at bit.ly/upstate2025 1 day CME to focus on the current SoC and updates from #ASCO25 in commonly treated solid and hematologic malignancies. Faculty: Roswell Park Wilmot Cancer Institute Andrea Apolo, M.D. Joshua Sabari, MD

Graduating from Roswell Park Hematology/Oncology Fellowship Jacobs School at University at Buffalo with conferral of the Dr. Gerald L Logue Memorial award has been an honor! A big thank you to my ever-supportive family, amazing mentors Roswell Park and my fabulous friends! Mom, I did it! This one is for you ❤️

We’ve been lucky to work with you!! Thank you for all the mentorship and support, Deepak Vadehra Dr. Vadehra! Keeping you on my speed dial 📱

Ending our didactics for the year on a #BREAKWATER #ATOMIC #NICHE with Deepak Vadehra!! Also, congratulations on your Best Teacher Award - Surg Onc at Roswell Park 👏👏👏

CLDN18 Expression and Isoform Distribution mainly in GI cancers. Trend of reduced overall CLDN18 expression after chemo with decrease CLDN18.2/18.1 proportion. Need similar analysis of isoform switch after chemo+Zolbe OncoAlert onlinelibrary.wiley.com/doi/10.1111/ca…

Insightful editorial by Dr Mike Pishvaian discussing TTF for LAPC (PANOVA-3)- ⚠️ Caveats: • High dropout rate (~29%) • Device compliance was suboptimal (62%), TTF requires to be in place for 18 hours for 6 months or more. • Trial lacked central eligibility review—possible

New in Journal of Clinical Oncology proof of-concept phase II trial shows lean body mass–based oxaliplatin dosing in stage III colon cancer reduces neurotoxicity vs. standard BSA-based dosing, with no DFS compromise. #GIonc #CRC #OncoResearch ascopubs.org/doi/10.1200/JC…

Grateful to be part of this study which is finally published! Thanks to our research team, and the patients. I saw firsthand the lives touched by this trial. Clinical research is always, at its core, about them. Roswell Park Baptist Health Cancer Care Miami Cancer Institute Research academic.oup.com/oncolo/article…

First day as #GI Medical Oncologist at the Zuckerberg Cancer Center/Northwell Health - ready to hit the ground running and make an impact in #CancerCare!

Honored to receive the Dr. Gerald L. Logue award Jacobs School at University at Buffalo Roswell Park Hematology/Oncology Fellowship! 🏆 Grateful for my patients for trusting me, my mentors for guiding me and my family for supporting me always!

Our now ex-chief par excellence Riya Patel, MD , received the coveted Dr. Gerald L. Logue award this past year. We are sure she will continue to make us proud with her accomplishments and more importantly, her kindness.

Oncology fellows if you haven’t yet, please take 3 minutes to fill out this survey on your experience with sexual health counseling in cancer patients. Your input means a lot! ✨ Malak Alharbi Hem-Onc Fellows Network Arya Roy forms.gle/XHGLfdTJFeVT7e…

Our correspondence in The Lancet Oncology highlights critical aspects of the SANO trial. Commendable to see such bold, paradigm-shifting trials in oncology. 🔗 thelancet.com/journals/lanon… #LancetOncology Dr Amol Akhade erman akkuş Vanita Noronha, MBBS MD DM Tata Memorial Centre, Varanasi (MPMMCC & HBCH) bhawna sirohi

A new report from Dana-Farber highlights rising rates of GI cancers in young adults - not just #colorectal, but also #pancreatic, #esophageal, #gastric, #biliary & more. Dana-Farber's Young-Onset Colorectal Cancer Center Kimmie Ng, MD, MPH Sara Khosrowjerdi Char, MD Catherine O’Connor Read more: bit.ly/40D0kd8

🚨 We’re (I'm) hiring! 🚨 Looking for an experienced oncology APP (PA or NP) to join my clinic team. 1 day/week in Manhattan, 1 day/week in Long Island, and the rest supporting our growing practice (sadly, not actually a 2 day a week job). 🏥 💡 Focus is colorectal cancer — the

DG04 officially published NEJM ASCO. This comes 10 years after my first phase 1 patient. DG04 took 3.5+ years due to <15% HER2+ and fresh biopsy to confirm HER2. Grateful for global effort—hoping this expands T-DXd access worldwide nejm.org/doi/full/10.10… OncoAlert OncoDaily

Obrixtamig, a DLL3/CD3 IgG-like T-cell engager for SCLC and epNECs. Just out in JCO. Clearly efficacy in these hard-to-treat cancers and larger studies ongoing will hopefully confirm that. ascopubs.org/doi/10.1200/JC…

Targeting the YAP-SDC1 axis overcomes resistance to KRASi in GI cancers by blocking SDC1-driven macropinocytosis and RTK activation, offering a promising strategy for KRASi resistance. Wantong Yao Haoqiang Ying Cell Reports Medicine #crcsm To the clinic! pubmed.ncbi.nlm.nih.gov/40713971/

Representative case of zolbetuximab-induced gastritis that improved despite continued treatment. A case series with additional patients will be coming soon. esmogastro.org/article/S2949-… OncoAlert ESMO - Eur. Oncology

Final OS analysis of KN585 published in Journal of Clinical Oncology ASCO. OS HR has been changed from 0.90 at primary The Lancet Oncology to 0.86. HR in FLOT cohort also shifted from 1.02 to 0.81. Hoping MATTERHORN OS HR will also further improve with longer follow-up. ascopubs.org/doi/10.1200/JC…